Clinical usefulness of the CSF β-amyloid Aβ1-42/Aβ1-40 ratio for Alzheimer's disease diagnosis: a retrospective study in a Belgian academic hospital.
DEAR EDITOR, Diagnosing Alzheimer’s disease (AD) can sometimes be challenging. In addition to clinical semiology and brain-imaging techniques, much emphasis has been put during the last years on the biological hallmarks of AD. The usual markers measured in cerebrospinal fluid (CSF) are Total-Tau (T-Tau), Phospo-Tau (P-Tau) and β-amyloid 1–42 peptide (Aβ42). The diagnostic performance of these CSF markers is quite acceptable when used and interpreted together [.]
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Verlag/Hrsg.: |
Springer
|
Schlagwörter: | Alzheimer Disease / Amyloid beta-Peptides / Belgium / Biomarkers / Hospitals / University / Humans / Peptide Fragments / Retrospective Studies / Alzheimer / Aβ1-40 / Aβ1-42 / Cerebrospinal fluid / Ratio |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26527010 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/263470 |